Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical data is no easy task—especially when AC Immune’s research on misfolded proteins spans hundreds of pages of scientific detail and risk factors. If you have ever asked, "Where can I find AC Immune’s quarterly earnings report 10-Q filing?" or "How do I track AC Immune insider trading Form 4 transactions?", you know the challenge.
Stock Titan solves it. Our AI-powered summaries strip away jargon so you can understand AC Immune SEC documents with AI in minutes, not hours. From an annual report 10-K simplified to an 8-K material events explained, every document is accompanied by keyword-searchable highlights, real-time EDGAR updates, and context on why a disclosure matters. Need to monitor an unexpected clinical-trial halt? An alert appears the moment the 8-K posts. Curious about Form 4 insider transactions in real-time? Our dashboard surfaces each executive stock transaction and links it to the corresponding pipeline milestone.
The result is actionable clarity: AC Immune earnings report filing analysis that pinpoints R&D burn rate, a proxy statement executive compensation breakdown that connects pay to trial progress, and a timeline view of AC Immune executive stock transactions Form 4. Whether you’re screening for biotech catalysts, gauging partner revenue in a 10-Q, or simply need AC Immune SEC filings explained simply, everything lives here—updated the second AC Immune (ACIU) hits EDGAR.
AC Immune SA (ACIU) filed a Form 6-K summarizing the outcomes of its 19 June 2025 Annual General Meeting (AGM). All resolutions that remained on the agenda were approved by shareholders.
- Financial statements: 2024 IFRS consolidated and statutory financial statements received shareholder approval. The company posted a CHF 45.8 million net loss, lifting accumulated losses to CHF 356.8 million.
- Compensation report: The 2024 compensation report passed on an advisory basis. Shareholders also approved maximum board compensation of CHF 1.03 million for the period AGM 2025-AGM 2026 and executive-committee compensation of CHF 7.50 million for FY 2026.
- Board changes: Four directors—Monika Bütler, Carl June, Andrea Pfeifer, Roy Twyman—were re-elected. Renée Aguiar-Lucander joined the board, while Martin Zügel was elected both director and new chair. The same individuals were confirmed for the Compensation, Nomination & Corporate Governance Committee.
- Auditor & proxy: PwC SA was re-appointed as statutory auditor for 2025; Reymond & Associés remains independent proxy through 2026.
No new financial guidance, operational updates, or transaction announcements accompanied the filing. The exhibit list references a management presentation (Ex. 99.1) not included in the text.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
What is AC Immune's primary focus?
Which technologies does AC Immune use in its research?
How is AC Immune positioned within the biopharmaceutical industry?
What does AC Immune's product pipeline include?
How does AC Immune approach precision medicine?
What are the key features of AC Immune's clinical development strategy?
How does the company's research contribute to the field of neurodegeneration?
Does AC Immune engage in strategic collaborations?
